The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

Journal of the American Heart Association

Volumn 3, Issue 2, 2014, Pages

  Menne, Jan ^a   Ritz, Eberhard ^a   Ruilope, Luis M ^a   Chatzikyrkou, Christos ^a   Viberti, Giancarlo ^a   Haller, Hermann ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; KIDNEY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904708700     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000810     Document Type: Article

References (0)